Variable | Univariate | Multivariate | ||||||
---|---|---|---|---|---|---|---|---|
PFS | OS | PFS | OS | |||||
FIGO stage | ||||||||
 IV | 1.00 | (reference) | 1.00 | (reference) | 1.00 | (reference) | 1.00 | (reference) |
 IIIc | 3.03 | (0.35–13.66) | 4.24 | (0.52–6.95) | 2.28 | (0.30–4.10) | 3.57 | (0.48–6.46) |
Ascites | ||||||||
  > =500 ml | 1.00 | (reference) | 1.00 | (reference) | 1.00 | (reference) | 1.00 | (reference) |
  < 500 ml | 1.82 | (1.45–2.85) | 1.90 | (1.56–2.98) | 2.05 | (1.40–2.95) | 2.02 | (1.66–4.08) |
Outcome of surgery | ||||||||
 Suboptimal | 1.00 | (reference) | 1.00 | (reference) | 1.00 | (reference) | 1.00 | (reference) |
 Optimal | 1.52 | (1.15–2.42) | 1.66 | (1.22–2.50) | 1.93 | (1.75–2.84) | 2.20 | (1.40–4.24) |
Tumor sites | ||||||||
  > 3 | 1.00 | (reference) | 1.00 | (reference) | 1.00 | (reference) | 1.00 | (reference) |
  < = 3 | 1.32 | (1.12–1.80) | 1.49 | (1.25–2.25) | 1.26 | (0.94–1.74) | 1.40 | (0.85–2.04) |
Baseline CA-125 | 1.02 | (1.01–1.08) | 1.03 | (1.01–1.08) | 1.02 | (0.97–1.07) | 1.02 | (0.98–1.06) |
Preoperative CA-125 | 1.01 | (1.00–1.04) | 1.01 | (1.00–1.04) | 1.02 | (0.96–1.05) | 1.02 | (0.96–1.05) |
CA-125 decreasing kinetics | 1.02 | (1.00–1.04) | 1.02 | (1.00–1.04) | 1.01 | (1.00–1.04) | 1.01 | (1.00–1.05) |